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BACKGROUND: First- pass reperfusion (FPR) is associated with favorable outcome after endovascular treatment. It is unknown 
whether this effect is independent of patient characteristics and whether FPR has better outcomes compared with excellent 
reperfusion (Expanded Thrombolysis in Cerebral Infarction [eTICI] 2C- 3) after multiple- passes reperfusion. We aimed to evalu-
ate the association between FPR and outcome with adjustment for patient, imaging, and treatment characteristics to single 
out the contribution of FPR.
METHODS AND RESULTS: FPR was defined as eTICI 2C- 3 after 1 pass. Multivariable regression models were used to investigate 
characteristics associated with FPR and to investigate the effect of FPR on outcomes. We included 2686 patients of the MR 
CLEAN (Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands) Registry. 
Factors associated with FPR were as follows: history of hyperlipidemia (adjusted odds ratio [OR], 1.05; 95% CI, 1.01– 1.10), mid-
dle cerebral artery versus intracranial carotid artery occlusion (adjusted OR, 1.11; 95% CI, 1.06– 1.16), and aspiration versus stent 
thrombectomy (adjusted OR, 1.07; 95% CI, 1.03– 1.11). Interventionist experience increased the likelihood of FPR (adjusted OR, 
1.03 per 50 patients previously treated; 95% CI, 1.01– 1.06). Adjusted for patient, imaging, and treatment characteristics, FPR 
remained associated with a better 24- hour National Institutes of Health Stroke Scale (NIHSS) score (−37%; 95% CI, −43% to 
−31%) and a better modified Rankin Scale (mRS) score at 3 months (adjusted common OR, 2.16; 95% CI, 1.83– 2.54) compared 
with no FPR (multiple- passes reperfusion+no excellent reperfusion), and compared with multiple- passes reperfusion alone (24- 
hour NIHSS score, (−23%; 95% CI, −31% to −14%), and mRS score (adjusted common OR, 1.45; 95% CI, 1.19– 1.78)).
CONCLUSIONS: FPR compared with multiple- passes reperfusion is associated with favorable outcome, independently of pa-
tient, imaging, and treatment characteristics. Factors associated with FPR were the experience of the interventionist, history 
of hyperlipidemia, location of occluded artery, and use of an aspiration device compared with stent thrombectomy.
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Endovascular treatment (EVT) for acute isch-emic stroke aims to achieve recanalization of the occluded artery and reperfusion of the brain tissue as soon as possible. A higher reperfusion score (Expanded Thrombolysis in Cerebral Infarction [eTICI]) leads to a more favorable clinical outcome.1 
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Reperfusion can be achieved in one or multiple 
passes. Multiple passes are associated with a pro-
longed procedure time and occurrence of arterial 
endothelial injury.2– 4 Previous studies have described 
excellent reperfusion (eTICI 2C- 3) in one pass, first- 
pass reperfusion (FPR), as the optimal treatment 
result to pursue, because of its association with fa-
vorable clinical outcome.3,5
Despite this association, a causal relation between 
FPR and clinical outcome has not been established. FPR 
may depend on the interventionist and, perhaps even 
predominantly, on patient characteristics, which may in-
fluence the achievement of both FPR and good outcome.
The aim of this study was to assess characteris-
tics associated with FPR and whether an association 
of FPR with clinical outcome remains, after adjustment 
for these characteristics. Thereby, FPR will be com-
pared with patients without FPR and patients with ex-
cellent reperfusion after multiple passes.
METHODS
We used data from the MR CLEAN (Multicenter 
Randomized Clinical Trial of Endovascular Treatment 
for Acute Ischemic Stroke in the Netherlands) Registry. 
This is a prospective observational study in all 17 cent-
ers performing EVT in the Netherlands. All patients un-
dergoing EVT for acute ischemic stroke in the anterior 
circulation were registered in the MR CLEAN Registry. 
EVT was defined as entry into the angiography suite 
and receiving arterial puncture. Detailed study design 
and methods have been described previously.6 The 
central medical ethics committee of the Erasmus MC, 
University Medical Center, Rotterdam, the Netherlands, 
evaluated the study protocol and granted permission to 
perform the study as a registry (MEC- 2014- 235). With 
this approval, it was approved by the research board 
of each participating center. At UMC Utrecht, approval 
to participate in the study has been obtained from their 
own research board and ethics committee. The need 
for individual patient consent has been waived. In com-
pliance with the General Data Protection Regulation, 
source data are not available for other researchers. 
Information about analytic methods, study materials, 
and scripts of the statistical analyses is available from 
the corresponding author on reasonable request.
Patients
For the purpose of this study, we included the following 
patients who were: (1) aged ≥18 years, (2) had a groin 
puncture within 6.5 hours after stroke onset, (3) treated 
in a MR CLEAN Registry trial center, (4) had a proximal 
intracranial arterial occlusion in the anterior circulation 
(intracranial carotid artery/intracranial carotid artery ter-
minus or middle cerebral artery) demonstrated by com-
puted tomography angiography, magnetic resonance 
angiography, or digital subtraction angiography (DSA). 
These data concerned patients who were treated with 
EVT between March 18, 2014, and November 1, 2017.
Definition of FPR, Clinical, Imaging, and 
Treatment Characteristics
An imaging core laboratory analyzed all patient imag-
ing. The members of the core laboratory were blinded 
to all clinical data with the exception of symptom side. 
Reperfusion grade was measured according to the 
eTICI scale on final DSA.
CLINICAL PERSPECTIVE
What Is New?
• First- pass reperfusion (FPR) in patients who un-
derwent endovascular treatment for ischemic 
stroke caused by large- vessel occlusion is as-
sociated with better outcomes compared with 
no FPR, and compared with multiple- passes 
reperfusion, even after adjustment for patient, 
imaging, and treatment characteristics associ-
ated with FPR.
What Are the Clinical Implications?
• FPR should be the treatment target to pursue in 
every patient with an acute ischemic stroke of 
the anterior circulation treated with endovascu-
lar treatment.
• FPR could be used as a benchmark to measure 
good quality of stroke care, and interventionists 
should be trained to reach FPR.
Nonstandard Abbreviations and Acronyms
cOR common odds ratio
DSA digital subtraction angiography
eTICI Expanded Thrombolysis in Cerebral 
Infarction
EVT endovascular treatment
FPR first- pass reperfusion
MPR multiple- passes reperfusion
MR CLEAN Multicenter Randomized Clinical 
Trial of Endovascular Treatment for 
Acute Ischemic Stroke in the 
Netherlands
mRS modified Rankin scale
NER no excellent reperfusion
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FPR was defined as a single pass of the device 
without rescue treatment with intra- arterial thrombolyt-
ics, resulting in complete or near- complete reperfusion 
of the large- vessel occlusion and its downstream ter-
ritory, eTICI 2C- 3. Multiple- passes reperfusion (MPR) 
was defined as eTICI 2C- 3 after >1 pass or after 1 pass 
followed by rescue treatment with intra- arterial throm-
bolytics. No excellent reperfusion (NER) was defined 
as eTICI <2C independent of the number of passes.
Patient characteristics included the following vari-
ables: age, sex, history of atrial fibrillation, history of 
hypertension, history of diabetes mellitus, history of 
myocardial infarction, history of peripheral artery dis-
ease, history of stroke, history of hyperlipidemia, smok-
ing, use of antiplatelets, use of vitamin K antagonists, 
use of direct oral anticoagulants, National Institutes of 
Health Stroke Scale (NIHSS) score at baseline, and 
prestroke modified Rankin Scale (mRS) score.
Imaging characteristics included the following: loca-
tion of occluded artery, clot burden score, collaterals, 
hyperdense artery sign, Alberta stroke program early 
computed tomography score, intracranial atheroscle-
rosis, carotid artery occlusion at symptomatic side, 
carotid artery stenosis >50% at symptomatic side, and 
carotid artery dissection at symptomatic side.
Treatment characteristics included the following: 
time from onset to presentation intervention hospital, 
door (intervention hospital) to groin time, intravenous 
alteplase treatment, general anesthesia, aspiration de-
vice, and use of balloon- guided catheter.
Interventionists’ experience was defined as the ab-
solute number of patients treated before the current 
intervention. In this way, each patient received an ex-
perience number. If >1 interventionist was registered 
on a treatment, we counted the experience number 
of the most experienced interventionist. Experience 
is based on the number of EVTs in the MR CLEAN 
Registry studies since 2002 as well as on experience 
outside these studies, as reported by the intervention-
ists in response to a questionnaire conducted in 2019.
Outcomes
As primary outcome, we used the score on the NIHSS 
at 24  hours, because this is more closely related to 
EVT and reperfusion,7 whereas longer- term functional 
outcomes reflect factors above and beyond the EVT. In 
addition, NIHSS score at 24 hours has a good predic-
tive value for long- term stroke outcome.8– 10 We used 
the 3- month mRS score as a secondary outcome.11 
Study staff were instructed to assess mRS scores at 
90 days (±14 days).
Missing Data
All baseline data are reported as crude. If successful 
reperfusion was not achieved during EVT, we used the 
time of last contrast bolus injection as the final rep-
erfusion time. For the use in regression models, we 
imputed missing data using multiple imputation with 
R (package, MICE) based on relevant covariates and 
outcomes.
All missing eTICI scores were imputed. Reperfusion 
grade can only be reliably assessed when both antero-
posterior and lateral views on postintervention DSA are 
available.12 Reperfusion scores of patients assessed 
in a single projection (anteroposterior or lateral only) 
that were scored as eTICI 2A or higher were therefore 
recoded as missing and imputed. We retrospectively 
scored missing NIHSS scores using the neurological 
examination, as reported in the patient’s medical chart. 
Previous studies have found that retrospective NIHSS 
scoring is reliable.13,14 Any mRS score of 0 to 5 at fol-
low- up, assessed within 30  days of symptom onset, 
was considered invalid and treated as missing.
Statistical Analysis
We compared baseline characteristics of patients with 
FPR, MPR, and NER using descriptive statistics.
To investigate the association between these char-
acteristics and FPR, we used a multivariable logistic 
regression model with a backward stepwise selection 
procedure with 4 steps. In each additional step, vari-
ables with a P>0.2 were dropped, except for age and 
sex, which were forced into the model. In step 1, we 
tested all patient characteristics. In step 2, we added all 
imaging characteristics. In step 3, we added treatment 
characteristics. In step 4, we added interventionists’ 
experience. The final model consisted of all variables 
with a P≤0.2.
We analyzed the association between FPR and 
outcomes, adjusted for predictors of FPR: patient, 
imaging, and treatment characteristics. First, we 
compared outcomes between FPR and no FPR (ie, 
MPR+NER). Second, we compared FPR with MPR. 
Part of the mechanism of FPR is the faster procedure 
in patients with FPR compared with patients without 
FPR; therefore, we did not add this variable to the 
stepwise selection procedure to select variables as-
sociated with FPR. However, we did an extra anal-
ysis of the association between FPR and outcomes 
in which we added door- to- reperfusion time and 
procedure time to the adjustments. We used a lin-
ear regression model to analyze the NIHSS score at 
24 hours and presented coefficients (β) with 95% CIs. 
Patients who had died before the time point of NIHSS 
assessment was reached received the maximum 
NIHSS score of 42. The NIHSS score was then log10 
transformed, to better meet the assumption of nor-
mally distributed residuals in linear regression9 (Figure 
S1), and we added 1 point to the NIHSS, so the orig-
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addition to the percentage change in NIHSS analyzed 
with a linear regression model we also used a dichot-
omized NIHSS (an improvement of ≥8 points in NIHSS 
at 24 hours or reaching 0– 1 at 24 hours) analyzed with 
a logistic regression model. We used an ordinal logis-
tic regression model to analyze the outcome mRS at 
3  months and presented common odds ratio (cOR) 
with 95% CI. We used the inverse of the mRS score 
for each patient. We did a sensitivity analysis with a 
linear mixed model with random intercepts for hospi-
tals and the primary outcome, NIHSS at 24 hours, to 
account for patient clustering within each hospital. All 
statistical analyses were performed with R statistical 
software (version 3.6.1).
RESULTS
In total, 3637 patients were registered in the MR CLEAN 
Registry between March 18, 2014, and November 1, 
2017. First, we excluded 457 patients, mostly because 
of occlusion in the posterior circulation or treatment 
starting after 6.5  hours from the onset of symptoms 
(Figure  1). Second, we excluded 24 patients with an 
M3 or A2 occlusion. Third, we excluded 470 patients 
who did not receive mechanical thrombectomy, be-
cause arterial access to the intracranial vasculature 
was not achieved, or who had spontaneous reper-
fusion on DSA before EVT. Therefore, 2686 patients 
were included. In 555 of 2686 patients, we could not 
Figure 1. Flowchart of MR CLEAN (Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic 
Stroke in the Netherlands) Registry patients selected for analysis.
DSA indicates digital subtraction angiography; eTICI, expanded TICI; EVT, endovascular treatment; FPR, first- pass reperfusion; MPR, 
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Table 1. Baseline Characteristics of Patients With FPR, MPR, NER, and UPR
Characteristics FPR (n=511) MPR (n=548) NER (n=1072) UPR (n=555)
Patient characteristics
Age, y 72 (61– 80), 511 71 (62– 79), 548 71 (61– 81), 1072 71 (60– 79), 555
Men 51 (259/511) 55 (301/548) 52 (553/1072) 54 (297/555)
Atrial fibrillation 25 (126/500) 24 (132/544) 25 (267/1060) 20 (107/550)
Hypertension 51 (256/504) 53 (285/536) 52 (550/1051) 53 (286/544)
Diabetes mellitus 18 (91/508) 17 (94/545) 13 (142/1065) 16 (90/549)
Myocardial infarction 17 (85/499) 15 (82/538) 13 (134/1058) 14 (75/541)
Peripheral artery disease 9 (45/503) 9 (49/540) 9 (94/1048) 9 (49/540)
Previous ischemic stroke 15 (78/507) 16 (87/544) 18 (192/1066) 17 (84/547)
Hyperlipidemia 35 (171/488) 29 (154/529) 30 (306/1023) 32 (171/534)
Current smoking 27 (104/392) 26 (103/404) 30 (247/833) 32 (134/426)
Medication use
Antiplatelets 33 (166/503) 31 (170/547) 30 (317/1058) 32 (174/543)
Vitamin K antagonists 14 (71/506) 13 (73/546) 14 (145/1064) 11 (60/550)
Direct oral anticoagulants 4 (21/503) 2 (13/547) 4 (38/1058) 3 (18/546)
Baseline NIHSS score 16 (11– 19), 500 16 (12– 20), 544 16 (12– 19), 1053 16 (11– 19), 546
Prestroke modified Rankin stroke scale score
0 67 (333/500) 71 (384/540) 66 (690/1047) 71 (381/537)
1 26 (72/500) 13 (68/540) 13 (134/1047) 13 (72/537)
2 8 (41/500) 7 (40/540) 8 (82/1047) 6 (34/537)
≥3 11 (54/500) 9 (48/540) 13 (141/1047) 9 (50/537)
Imaging characteristics
Level of occlusion*
ICA 4 (19/500) 4 (23/527) 5 (51/1027) 7 (36/527)
ICA- T 15 (76/500) 26 (139/527) 24 (245/1027) 22 (114/527)
M1 68 (340/500) 58 (306/527) 58 (593/1027) 56 (293/527)
M2 13 (65/500) 11 (59/527) 13 (138/1027) 16 (84/527)
Hyperdense artery sign 54 (272/502) 58 (308/531) 56 (570/1023) 56 (300/535)
Clot burden score 6 (5– 8), 416 6 (4– 8), 440 6 (4– 8), 840 6 (4– 8), 428
Collaterals
Grade 0 5 (26/487) 6 (29/519) 7 (68/1016) 7 (38/517)
Grade 1 36 (174/487) 36 (185/519) 37 (373/1016) 38 (196/517)
Grade 2 38 (184/487) 43 (221/519) 39 (391/1016) 36 (185/517)
Grade 3 21 (103/487) 16 (84/519) 18 (184/1016) 19 (98/517)
ASPECTS 9 (8– 10), 505 9 (8– 10), 534 9 (7– 10), 1035 9 (8– 10), 538
Intracranial atherosclerosis 60 (300/498) 61 (321/527) 59 (609/1029) 59 (313/527)
Carotid artery occlusion at 
symptomatic side
8 (37/461) 11 (54/483) 10 (96/957) 15 (68/469)
Carotid artery stenosis >50% at 
symptomatic side
10 (46/461) 8 (36/483) 10 (91/957) 9 (43/469)
Carotid artery dissection at 
symptomatic side
3 (12/461) 4 (19/483) 4 (40/957) 4 (17/469)
Treatment characteristics
Time from onset to presentation 
intervention hospital, min
133 (64– 188), 457 135 (66– 185), 520 133 (64– 188), 1018 126 (55– 184), 522
Transfer from primary stroke center 55 (282/510) 57 (312/548) 55 (593/1072) 52 (286/555)
Intravenous alteplase treatment 76 (388/509) 75 (410/546) 75 (803/1070) 76 (421/553)
Onset- to- IVT time, min 79 (62– 115), 358 79 (60– 115), 379 83 (61– 122), 740 80 (61– 120), 392
Time between IVT and groin 
puncture, min
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classify reperfusion status as FPR, MPR, or NER. In 
this unclassified pass reperfusion group, in 348 pa-
tients, the number of attempts was missing; in 47 
patients, there was a missing eTICI score; and in 160 
patients, the eTICI score was assessed on one view of 
the postintervention DSA and so recoded as missing. 
In the remaining 2131 of 2686 patients, 511 of 2131 
(24%) patients met the criteria for FPR, 548 of 2131 
(26%) patients met the criteria for MPR, and 1072 or 
2131 (50%) patients met the criteria for NER. Baseline 
characteristics of the FPR, MPR, NER, and unclassi-
fied pass reperfusion groups are shown in Table 1.
Characteristics Associated With FPR
First, we analyzed patient, imaging, and treatment 
characteristics in patients with FPR compared with 
patients without FPR (MPR+NER). Of the patient 
characteristics, a history of hyperlipidemia was as-
sociated with FPR (adjusted odds ratio [aOR], 1.05; 
95% CI, 1.01– 1.10). For the imaging characteris-
tics, middle cerebral artery compared with intrac-
ranial carotid artery occlusion was associated with 
FPR (aOR, 1.11; 95% CI, 1.06– 1.16). For treatment 
characteristics, aspiration compared with stent 
thrombectomy was associated with FPR (aOR, 
1.07; 95% CI, 1.03– 1.11). Furthermore, intervention-
ists’ experience was associated with achieving FPR 
(aOR, 1.03 per 50 patients previously treated; 95% 
CI, 1.01– 1.06) (Table 2).
In the secondary analysis, characteristics associ-
ated with FPR compared with MPR were the following: 
use of direct oral anticoagulants (aOR, 1.19; 95% CI, 
1.00– 1.40), middle cerebral artery versus intracranial 
carotid artery occlusion (aOR, 1.17; 95% CI, 1.09– 1.26), 
door- to- groin time (aOR, 1.01 per 10 minutes; 95% CI, 
1.00– 1.02), general anesthesia (aOR, 0.93; 95% CI, 
0.87– 0.99), and aspiration versus stent thrombectomy 
(aOR, 1.11; 95% CI, 1.04– 1.18) (Table 3).
Association Between FPR and Outcome
In the univariable regression analyses, FPR led to a 
decrease in 24- hour NIHSS score (−38%; 95% CI, 
−44% to −32%), and a more favorable mRS score at 
3 months (cOR, 2.02; 95% CI, 1.73– 2.38), compared 
with patients without FPR (Table 4). These results were 
similar in analyses of FPR on a dichotomized NIHSS 
(2.58; 95% CI, 2.13– 3.13). The distribution of 24- hour 
NIHSS is shown in Figure S2.
Adjusted for patient, imaging, and treatment char-
acteristics, patients with FPR compared with patients 
Characteristics FPR (n=511) MPR (n=548) NER (n=1072) UPR (n=555)
Onset- to- groin time, min 191 (150– 248), 509 185 (145– 240), 547 195 (150– 255), 1067 190 (150– 245), 552
Door- to- groin time, min† 62 (37– 90), 475 55 (35– 80), 500 59 (35– 92), 971 63 (36– 94), 501
Procedure time, min 38 (30– 50), 487 67 (50– 90), 519 75 (54– 100), 1000 67 (45– 90), 530
Off- hours treatment‡ 64 (327/511) 57 (314/548) 65 (697/1072) 64 (357/555)
General anesthesia 31 (155/501) 34 (184/536) 25 (259/1043) 19 (93/482)
Aspiration§ 32 (159/479) 27 (139/523) 24 (243/1031) 27 (52/196)
Balloon- guided catheter 67 (268/398) 63 (270/427) 66 (558/849) 62 (228/371)
Experience of the interventionist
No. of previous procedures per 
interventionist
41 (23– 69), 499 40 (22– 68), 528 35 (16– 61), 1037 32 (15– 63), 519
Post eTICI
0 0 0 20 (218/1072) NA
1 0 0 7 (72/1072)
2A 0 0 30 (316/1072)
2B 0 0 44 (466/1072)
2C 24 (121/511) 30 (164/548) 0
3 76 (390/511) 70 (384/548) 0
Median No. of attempts 1 3 (2– 4) 2 (1– 4) NA
Categorical variables are presented as percentage (number/total number). Continuous variables are presented as median (interquartile range), total number. 
ASPECTS indicates Alberta stroke program early computed tomography score; eTICI, Expanded Thrombolysis in Cerebral Infarction; FPR, first- pass reperfusion; 
ICA, intracranial carotid artery; ICA- T, ICA terminus; IVT, intravenous alteplase treatment; M1/M2, middle cerebral artery; MPR, multiple- passes reperfusion; NA, 
not applicable; NER, no excellent reperfusion; NIHSS, National Institutes of Health Stroke Scale; and UPR, unclassified pass reperfusion.
*On the basis of computed tomographic angiography.
†Door intervention center.
‡Admission between 5:00 pm and 8:00 am, on weekends, or a national holiday.
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without FPR had lower 24- hour NIHSS scores (−37%; 
95% CI, −43% to −31%) and a more favorable mRS 
score (adjusted cOR, 2.16; 95% CI, 1.83– 2.54). These 
results were similar in analyses of FPR on a dichot-
omized NIHSS (aOR, 2.65; 95% CI, 2.18– 3.22). The 
result remained when FPR was compared with MPR: 
24- hour NIHSS (−23%; 95% CI, −31% to −14%), dichot-
omized NIHSS (aOR, 1.67; 95% CI, 1.29– 2.15), and 
mRS (adjusted cOR, 1.45; 95% CI, 1.19– 1.78) (Table 4 ). 
In Figure 2, the distribution of the mRS is shown. The 
odds ratios for each dichotomization of the mRS are 
shown in Table S1.
Procedure time in patients with FPR is shorter 
than in patients without FPR (Table  1). When door- 
to- reperfusion time was added to the adjustments 
instead of door- to- groin time, there was still a benefit 
of FPR on outcome, 24- hour NIHSS (−23%; 95% CI, 
−31% to 14%) and mRS at 3 months (adjusted cOR, 
1.42; 95% CI, 1.16– 1.74), compared with patients with 
MPR. However, when we made a breakdown of door- 
to- reperfusion time into door- to- groin time and proce-
dure time and we adjusted for these 2 time intervals, 
the effect of FPR over MPR was reduced, and just not 
significant anymore: 24- hour NIHSS (−10%; 95% CI, 
−21% to 2%) and mRS at 3  months (adjusted cOR, 
1.17; 95% CI, 0.93– 1.47).
In the sensitivity analysis, with a linear mixed model, 
we found the same association between FPR and 
the NIHSS score at 24 hours (Table S2), as shown in 
Table 4.
DISCUSSION
In our study, FPR is associated with favorable neuro-
logical and clinical outcomes, independent of patient, 
imaging, and treatment characteristics. Even when pa-
tients with FPR are compared with patients with MPR, 
FPR is associated with favorable neurological and clini-
cal outcomes.
Our results confirm that FPR should be the treat-
ment target to pursue in every patient treated with EVT. 
FPR could be used as a benchmark to measure good 
quality of stroke care, and interventionists should be 
trained to reach FPR.
Our results are in line with other observational studies 
that suggested that patients with FPR had better out-
comes than patients without FPR (MPR+NER).3,5,15,16 
Unlike NER patients, patients with FPR have excellent 
eTICI scores by definition; therefore, we compared the 
effect of FPR versus MPR and found that there was still a 
benefit of FPR on outcome. Most of the other studies that 
investigated the effect of FPR versus MPR on outcomes 
found a positive effect of FPR on outcome compared 
with a group of patients with MPR.3,5,17 One study with 
patients with excellent reperfusion (eTICI 2C- 3) found no 
significant difference in functional outcomes between 1, 
2, and ≥3 passes groups.18 However, in the same study, 
good functional outcomes were more likely in a dichot-
omized first- pass group versus non– first- pass group 
comparison, suggesting that the initial analysis was un-
derpowered. In another study, functional independence 
was achieved more often in patients with FPR, but the 
difference was not statistically significant.19
We made adjustments for patient, imaging, and 
treatment characteristics associated with FPR, in a hi-
erarchical way, to single out the contribution of FPR on 
outcomes. Even with these substantial adjustments, 
we found a benefit of FPR versus MPR on clinical 
outcomes. In the multilevel analysis, we showed that 
clustering and between- hospital differences in out-
come did not influence our results and conclusions. 
The benefit of FPR over MPR or NER might be ex-
plained by shorter procedures times, and lower num-
ber of passes. Obviously, procedure times with FPR 
are shorter than without FPR. When we adjusted the 
outcome for door- to- reperfusion time, there was still a 
benefit of FPR on outcome, although smaller. However, 
adjustment for procedure time separately reduced 
Table 2. Strength of the Association Between Patient, 
Imaging, and Treatment Characteristics and FPR Versus No 




Ratio (95% CI) P Value
Patient characteristics
Age per 10 y 1.01 (0.99– 1.02) 0.41
Men 0.99 (0.96– 1.02) 0.47
Hypertension 0.97 (0.93– 1.00) 0.08
Diabetes mellitus 1.03 (0.98– 1.08) 0.19
Previous ischemic stroke 0.97 (0.92– 1.01) 0.15
Hyperlipidemia 1.05 (1.01– 1.10) 0.02
Imaging characteristics
Level of occluded artery*
ICA- T Reference
ICA 1.02 (0.94– 1.11) 0.59
M1 1.11 (1.06– 1.16) <0.001
M2 1.07 (1.00– 1.14) 0.05
Treatment characteristics
Door- to- groin time, per 10 min† 1.003 (1.00– 1.01) 0.13
Aspiration device‡ 1.07 (1.03– 1.11) <0.001
Experience of the interventionist
No. of previous procedures, per 50 1.03 (1.01– 1.06) 0.01
FPR indicates first- pass reperfusion; ICA, intracranial carotid artery; 
ICA- T, ICA terminus; M1/M2, middle cerebral artery; MPR, multiple- passes 
reperfusion; and NER, no excellent reperfusion.
*On the basis of computed tomographic angiography.
†Door intervention hospital.
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the effect on 24- hour NIHSS by half, suggesting that 
the effect of FPR was explained for a large part, but 
not completely, by procedure time, which was also 
found in previous studies.3,5 Another explanation for 
better outcomes in patients with FPR compared with 
patients with MPR could be a reduction in complica-
tions, vessel wall damage, thrombus migration, and 
embolization.2– 4,20,21
Characteristics Associated With FPR
A history of hyperlipidemia was associated with FPR. 
We cannot explain this association, and this could 
well be caused by chance. However, this could also 
suggest that stroke etiology influences the chance 
of reaching FPR. We did not have information about 
stroke etiology or clot histological features/character-
istics to investigate the relationship of FPR with stroke 
etiology. In patients with FPR, a middle cerebral artery 
occlusion was more common, which is in line with 
previous studies.3,16 At this location, the thrombus is 
probably easier to remove. Previous studies indicated 
an association between FPR and the use of balloon- 
guided catheter.3,17,22 This could not be confirmed 
in our study. In our Results, aspiration compared 
with stent thrombectomy increased the likelihood of 
reaching FPR. In the Contact Aspiration versus Stent 
Retriever for Successful Revascularization (ASTER) 
trial, similar rates of FPR were achieved with an as-
piration and a stent retriever.23 These patients were 
randomly assigned to an endovascular procedure with 
a stent retriever or aspiration. The choice of endovas-
cular technique in our cohort was not random, which 
could give a bias to our results. Furthermore, no details 
were available on the type of aspiration approach that 
was used.
In our Results, the experience of the interventionist 
was associated with reaching FPR. Previous observa-
tional studies, with data from 2010 to 2011, showed, in 
a limited setting, no significant effect of intervention-
ists’ experience on recanalization, the duration of the 
Table 3. Strength of the Association Between Patient, 





Ratio (95% CI) P Value
Patient characteristics
Age per 10 y 1.01 (0.99– 1.04) 0.38
Men 0.96 (0.91– 1.02) 0.15
Hypertension 0.94 (0.87– 1.00) 0.06
Hyperlipidemia 1.07 (0.99– 1.16) 0.07
Use of direct oral anticoagulants 1.19 (1.00– 1.40) 0.04
Imaging characteristics
Level of occluded artery*
ICA- T Reference
ICA 1.09 (0.94– 1.28) 0.25
M1 1.17 (1.09– 1.26) <0.001
M2 1.15 (1.02– 1.28) 0.02
Carotid artery stenosis† 1.10 (0.98– 1.24) 0.10
Treatment characteristics
Intravenous alteplase treatment 1.05 (0.98– 1.13) 0.15
Door- to- groin time, per 10 min‡ 1.01 (1.00– 1.02) 0.003
General anesthesia 0.93 (0.87– 0.99) 0.03
Aspiration device§ 1.11 (1.04– 1.18) 0.002
FPR indicates first- pass reperfusion; ICA, intracranial carotid artery; ICA- 
T, ICA terminus; M1/M2, middle cerebral artery; and MPR, multiple- passes 
reperfusion.
*On the basis of computed tomographic angiography.
†Carotid artery stenosis >50% at symptomatic side.
‡Door intervention hospital.
§The other used device is stent retriever.





 http://ahajournals.org by on O
ctober 25, 2021
J Am Heart Assoc. 2021;10:e019988. DOI: 10.1161/JAHA.120.019988 9
den Hartog et al First- Pass Reperfusion and EVT for Ischemic Stroke
procedure, occurrence of serious adverse events, and 
neurological and functional outcomes.24 Since then, 
interventionists are more experienced, and we have 
more observations on interventions. Thus, larger num-
bers might unveil the potential association of the inter-
ventionist’s experience with FPR.
Limitations
The patient data were collected retrospectively. 
Therefore, we used strict definitions of outcomes, and 
all our imaging was assessed by an independent core 
laboratory. Registries in general are prone to missing 
and incorrect values. However, all data were verified 
by our study coordinators.25 We used strict definitions 
of missing values. For instance, all mRS scores of 0 to 
5 at follow- up, assessed within 30 days of symptom 
onset, were considered invalid and treated as miss-
ing; and all reperfusion scores of eTICI 2A or above, 
assessed on a single- direction DSA, were recoded as 
missing. These missing values were imputed by means 
of multiple imputation.6,26
We used the number of previously performed pro-
cedures as an estimate of the interventionist’s ex-
perience. Further research is needed to assess the 
contribution of interventionist’s skills to improved out-
comes. In the multivariable analysis, only few factors 
were associated with FPR. We likely need variables 
that provide more detailed and to the point description 
of the morphological features of the vascular tree and 
the occlusive lesion to explain the variance in occur-
rence of FPR and its association with outcome.
CONCLUSIONS
FPR compared with MPR is associated with favora-
ble outcome, independently of patient, imaging, and 
treatment characteristics. Factors associated with 
FPR were the experience of the interventionist, his-
tory of hyperlipidemia, location of occluded artery, 
and use of an aspiration device compared with stent 
thrombectomy.
APPENDIX
MR CLEAN (Multicenter Randomized 
Clinical Trial of Endovascular Treatment 
for Acute Ischemic Stroke in the 
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University Medical Center and Cardiovascular 
Research Institute Maastricht), Wim H. van Zwam 
(Department of Radiology and Nuclear Medicine, 
Maastricht University Medical Center and 
Cardiovascular Research Institute Maastricht), Jelis 
Boiten (Department of Neurology, Haaglanden 
Medical Center, The Hague), Jan Albert Vos 
(Department of Radiology, Sint Antonius Hospital, 
Nieuwegein), Ivo G. H. Jansen (Department of 
Radiology and Nuclear Medicine, Amsterdam UMC, 
University of Amsterdam, Amsterdam), Maxim J. H. 
L. Mulder (Department of Neurology, Radiology and 
Nuclear Medicine, Erasmus MC, University Medical 
Center, Rotterdam), Robert- Jan B. Goldhoorn 
(Department of Neurology, Radiology and Nuclear 
Medicine, Maastricht University Medical Center and 
Cardiovascular Research Institute Maastricht), Kars 
C. J. Compagne (Department of Radiology and 
Nuclear Medicine, Erasmus MC, University Medical 
Center, Rotterdam), Manon Kappelhof (Department 
of Radiology and Nuclear Medicine, Amsterdam 
UMC, University of Amsterdam, Amsterdam), Josje 
Brouwer (Department of Radiology and Nuclear 
Medicine, Amsterdam UMC, University of 
Table 4. Univariable and Multivariable Linear/Ordinal Logistic Regression for the Association Between FPR and 24- Hour 
NIHSS Score and mRS Score at 3 Months
Variable
NIHSS Score at 24 h, % mRS Score at 3 mo
β (95% CI) aβ (95% CI) cOR (95% CI) acOR (95% CI)
FPR vs no FPR −38 (−44 to −32) −37 (−43 to −31)* 2.02 (1.73 to 2.38) 2.16 (1.83 to 2.54)*
FPR vs MPR −25 (−33 to −17) −23 (−31 to −14)† 1.44 (1.19 to 1.75) 1.45 (1.19 to 1.78)†
No FPR=MPR (Expanded Thrombolysis in Cerebral Infarction [eTICI] ≥2C in multiple passes)+no excellent reperfusion (eTICI <2C, independent of number of 
passes). acOR indicates adjusted cOR; cOR, common odds ratio; FPR, first- pass reperfusion; MPR, multiple- passes reperfusion; mRS, modified Rankin Scale; 
and NIHSS, National Institutes of Health Stroke Scale.
*Adjusted for age, sex, diabetes mellitus, hypertension, previous stroke, hyperlipidemia, level of occluded artery, door- to- groin time, and aspiration device.
†Adjusted for age, sex, hypertension, hyperlipidemia, use of direct oral anticoagulants, level of occluded artery, carotid artery stenosis >50% at symptomatic 
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Table S1. Odds ratio for all dichotomizations of mRS, first pass reperfusion compared to 
multiple pass reperfusion. 
mRS 
cut point 
FPR versus MPR 
OR (95%CI) 
FPR versus MPR 
aOR (95%CI) * 
0-1 2.95 (2.51-3.46) 26.52 (13.74-51.20) 
1-2 2.37 (2.03-2.77) 20.87 (10.85-40.15) 
2-3 1.48 (1.28-1.71) 12.23 (6.41-23.32) 
3-4 0.86 (0.74-1.00) 6.60 (3.49-12.48) 
4-5 0.33 (0.28-0.38) 2.29 (1.22-4.31) 
5-6 0.07 (0.06-0.09) 0.48 (0.25-0.92) 
 
mRS modified Rankin Stroke scale, FPR first pass reperfusion, MPR multiple pass reperfusion, OR odds ratio, aOR 
adjusted odds ratio, CI confidence interval 
* adjusted for age, sex, hypertension, hyperlipidemia, use of direct oral anticoagulants, level of occluded artery, 
carotid artery stenosis >50% at symptomatic side, intravenous alteplase treatment, door to groin time, general 

















Table S2. Multilevel model with hospital as random intercept, the association between FPR 







* adjusted for age, sex, diabetes mellitus, hypertension, previous stroke, hyperlipidemia, level of occluded artery, 
door to groin time, aspiration device 
† adjusted for age, sex, hypertension, hyperlipidemia, use of direct oral anticoagulants, level of occluded artery, 
carotid artery stenosis >50% at symptomatic side, intravenous alteplase treatment, door to groin time, general 
anesthesia, aspiration device 
NIHSS, National Institutes of Health Stroke Scale, FPR, first pass reperfusion, MPR multiple pass reperfusion, no  











 NIHSS at 24 hours 
β (95%CI) aβ (95%CI) 
 
FPR vs no FPR -38% (-44 to -32) -37% (-42 to -31)* 































Figure S2. Distribution of unadjusted log10 transformed NIHSS at 24 hours (A) patients with  
FPR, (B) patients with MPR, (C) patients without FPR. 
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